CLINICAL TRIALS PROFILE FOR OXYBUTYNIN
✉ Email this page to a colleague
All Clinical Trials for OXYBUTYNIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00170768 ↗ | Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over | Completed | Novartis | Phase 2 | 2005-02-01 | The purpose of this study is to explore the possible cognitive effects of darifenacin modified release and long-acting oxybutynin. |
| NCT00175123 ↗ | Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele | Unknown status | Aarhus University Hospital | Phase 4 | 2005-05-01 | The purpose of this study is to examine how injection of botulinum toxin in the bladder affects bladder function. The trial is carried out in children born with malformation of the spinal cord and subsequent overactive bladders. The purpose of treating the bladder (with different drugs) is to prevent damage to the kidneys and renal function. The aim of this study is to compare a conventionally used drug (oxybutynin) with botulinum toxin. The hypothesis of the study is that botulinum toxin is equal to oxybutynin in the treatment of overactive bladder. |
| NCT00175123 ↗ | Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele | Unknown status | University of Aarhus | Phase 4 | 2005-05-01 | The purpose of this study is to examine how injection of botulinum toxin in the bladder affects bladder function. The trial is carried out in children born with malformation of the spinal cord and subsequent overactive bladders. The purpose of treating the bladder (with different drugs) is to prevent damage to the kidneys and renal function. The aim of this study is to compare a conventionally used drug (oxybutynin) with botulinum toxin. The hypothesis of the study is that botulinum toxin is equal to oxybutynin in the treatment of overactive bladder. |
| NCT00223821 ↗ | Enhancing Conservative Treatment for Urge Incontinence | Completed | US Department of Veterans Affairs | N/A | 2003-09-01 | The primary objective of this project is to evaluate whether enhancing drug therapy with components of behavioral training, including pelvic floor muscle rehabilitation, results in better outcomes than drug therapy alone for urge incontinence in community-dwelling women. |
| NCT00223821 ↗ | Enhancing Conservative Treatment for Urge Incontinence | Completed | VA Office of Research and Development | N/A | 2003-09-01 | The primary objective of this project is to evaluate whether enhancing drug therapy with components of behavioral training, including pelvic floor muscle rehabilitation, results in better outcomes than drug therapy alone for urge incontinence in community-dwelling women. |
| NCT00224016 ↗ | Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition | Completed | Watson Pharmaceuticals | Phase 4 | 2004-12-01 | This study will evaluate the safety and effectiveness of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in children who have a neurological condition (e.g. spina bifida) that contributes to their overactive bladder. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OXYBUTYNIN
Condition Name
Clinical Trial Locations for OXYBUTYNIN
Trials by Country
Clinical Trial Progress for OXYBUTYNIN
Clinical Trial Phase
Clinical Trial Sponsors for OXYBUTYNIN
Sponsor Name
